Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study

By: Contributor(s): Material type: TextTextPublication details: Lancet Haematol 2025Description: Apr;12(4):e282-e293Subject(s): Online resources:
Contents:
DOI: 10.1016/S2352-3026(24)00377-6
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Call number Status Date due Barcode
Article Article Deenanath Mangeshkar Hospital Not for loan A0348

DOI: 10.1016/S2352-3026(24)00377-6

There are no comments on this title.

to post a comment.

Powered by Koha